Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer
- 31 May 2006
- journal article
- research article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 42 (8), 1083-1092
- https://doi.org/10.1016/j.ejca.2006.01.029
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Intermittent androgen suppression for locally advanced and metastatic prostate cancer: Preliminary report of a prospective multicenter studyUrology, 2004
- Intermittent Androgen Deprivation Therapy for Prostate CancerThe Oncologist, 2004
- Age‐related changes in testosterone and the role of replacement therapy in older menClinical Endocrinology, 2004
- Why is prostate cancer screening so common when the evidence is so uncertain? a system without negative feedbackAmerican Journal Of Medicine, 2002
- Quality-of-Life Outcomes After Primary Androgen Deprivation Therapy: Results From the Prostate Cancer Outcomes StudyJournal of Clinical Oncology, 2001
- PROSTATE SPECIFIC ANTIGEN ONLY PROGRESSION OF PROSTATE CANCERJournal of Urology, 2000
- Quality of life in patients with prostatic carcinoma: A review and results of a study in N+ disease Prostate-specific antigen as predictor of quality of lifeUrological Research, 1997
- Health-related quality of life among patients with metastatic prostate cancerUrology, 1997
- The quality of life of patients with newly diagnosed M1 prostate cancer: Experience with EORTC clinical trial 30853European Journal Of Cancer, 1996
- Screening, early detection, and treatment of prostate cancer: A European viewUrology, 1995